右归丸对肾阳虚型慢性肾衰大鼠肾脏AQP2表达影响及机制研究
|
摘要
目的
水代谢平衡紊乱是慢性肾功能衰竭(CRF)最常见的临床表现之一,往往在CRF早期就出现,是能够导致肾功能急剧恶化的重要危险因素。因此及时纠正CRF早期水代谢平衡紊乱,对改善肾功能,延缓CRF病程进展,提高患者生存质量,具有重要意义。中医认为CRF基本病机属于肾阳虚,临床上采用温补肾阳方法治疗CRF也取得了较好的效果,但机理尚未阐明。本研究以分子生物学、形态学等检测技术,观察了温补肾阳传统名方右归丸对肾阳虚型慢性肾衰模型大鼠肾组织AQP2表达的影响,以及对血中AVP水平、肾组织中血管紧张素Ⅱ(AⅡ)水平、环磷酸腺苷(cAMP)水平、肾组织中血管紧张素ⅡAT1受体(AT1R)表达、环氧合酶2(COX-2)表达、蛋白激酶A(PKA)表达的影响,旨在从分子水平探讨右归丸治疗慢性肾衰水液代谢平衡紊乱的药理作用机制,并为肾阳虚证“气化不利”的病理生理学机制提供实验依据。
方法
1.动物造模及给药
健康雄性Wistar大鼠随机分为对照组、模型组、右归丸组及替米沙坦组。模型组、右归丸组及替米沙坦组大鼠每日上午按200mg/kg/d给予2%的腺嘌呤混悬液灌服,建立肾阳虚型慢性肾衰大鼠模型,对照组大鼠给予相应量蒸馏水灌胃,连续21天。从造模的第3周开始,右归丸组及替米沙坦组大鼠每日上午灌服腺嘌呤的同时,开始每日下午分别灌服右归丸(按3.6 g/kg/d)及替米沙坦(按5.4mg/Kg/d),对照组及模型组大鼠给予相应量蒸馏水灌胃,连续21天。
2.指标观察
实验过程中,观察大鼠的一般状态、体重、尿量、尿比重、血Scr、BUN含量及肾组织病理形态的变化;采用免疫组化及Western blot方法测定大鼠肾组织AQP2表达;采用放射性免疫方法检测大鼠血AVP含量、肾组织AⅡ及cAMP含量;采用免疫组化方法检测肾组织PKA表达;利用Western blot方法测定大鼠肾组织AT1受体、COX-2蛋白表达,
3.统计学处理
计量资料用(?)±SD表示,采用SPSS10.0统计学软件进行ANOVA(完全随机设计的单因素方差分析)统计方法处理,以P＜0.05为有显著性差异。
结果
1.右归丸对肾阳虚型慢性肾衰大鼠肾功能影响
结果显示,模型组大鼠出现畏寒肢冷、食量减少、体重下降、活动减少;与对照组比较,尿量明显增加,尿比重下降,血Scr及BUN含量显著增高(P＜0.05),肾组织光镜观察可见肾小球囊腔扩大,间质纤维组织增生及大量炎细胞浸润,肾小管呈代偿性扩张。与模型组比较,右归丸组大鼠摄食较好、活动力较强、被毛较光泽、反应灵敏、体重均有不同程度增加,尿量减少、尿比重增加、血Scr及BUN含量下降(P＜0.05)、肾组织光镜观察可见病理损伤明显减轻。
2.右归丸对肾阳虚型慢性肾衰大鼠肾组织AQP2表达影响
免疫组化方法检测表明:模型组大鼠肾脏集合管上皮细胞胞膜胞浆AQP2的表达较对照组明显减弱,表现为细胞胞膜和胞浆棕黄色颗粒明显减少,颜色明显变浅,图像分析表明:模型组大鼠肾脏集合管上皮细胞AQP2阳性表达累积光密度值明显低于对照组(P＜0.05);右归丸组大鼠肾脏集合管上皮细胞胞膜胞浆AQP2的表达较模型组明显增强,表现为细胞胞膜胞浆棕黄色颗粒明显增多,颜色明显加深,图像分析结果显示:右归丸组大鼠肾脏集合管上皮细胞AQP2阳性表达累积光密度值明显高于模型组(P＜0.05)。western blot方法检测显示:模型组大鼠肾组织AQP2表达下降,表现为条带窄,密度小,颜色浅。图像分析结果显示:模型组大鼠AQP2表达条带灰度值显著低于对照组;右归丸组大鼠肾组织AQP2蛋白表达增加,表现为条带宽,密度大,颜色深,图像分析结果显示:右归丸组大鼠。肾组织AQP2表达条带灰度值显著高于模型组(P＜0.05)。
3.右归丸对肾阳虚型慢性肾衰大鼠血中AVP含量、肾组织中AⅡ、cAMP含量、AT1R表达等影响。
结果表明,三组大鼠血中AVP含量无显著性差异(P＞0.05)。与对照组比较,模型组大鼠肾组织AⅡ含量、AT!R及COX-2表达明显升高、cAMP含量及PKA表达显著下降(P＜0.05);与模型组比较,右归丸组大鼠肾组织中AⅡ含量、AT!R及COX-2表达明显降低、cAMP含量及PKA表达增加(P＜0.05)。
结果显示,慢性肾衰发生水代谢平衡紊乱的可能机制之一为肾脏集合管AQP2表达下降。中医理论的肾主水功能,主要体现在依靠肾的气化作用“升清降浊”以维持机体水液的动态平衡,当肾阳虚气化功能减退时则出现水液代谢障碍。由此推测:肾脏的气化功能减退的实质之一,可能通过AQP2表达的下调,影响了肾脏的重吸收功能。而肾组织AQP2表达下降的可能机制为,通过肾组织中AⅡ含量升高、AT1R及COX-2表达增加,导致肾组织中cAMP含量及PKA表达降低,使AQP2在肾脏的表达下降;采用右归丸治疗,通过温补肾阳,使肾组织中AⅡ含量、AT1R及COX-2表达降低,增加肾组织中cAMP含量及PKA表达,导致肾脏AQP2的表达增加,改善慢性肾衰水代谢平衡紊乱,保护肾功能,延缓慢性肾衰进展。
结论
1.肾阳虚型慢性肾衰模型大鼠尿量增加,尿比重降低;血Scr及BUN水平增加;肾组织病理可见明显损伤;右归丸治疗能够明显改善上述病理变化。
2.肾阳虚型慢性肾衰模型大鼠肾组织AQP2表达下调;右归丸治疗可使AQP2表达上调。
3.右归丸对肾阳虚型慢性肾衰模型大鼠血AVP含量无显著影响。
4.肾阳虚型慢性肾衰大鼠模型肾组织中AⅡ含量升高、AT1受体及COX-2表达上调、cAMP含量下降、PKA表达下调。
5.右归丸使肾组织中AⅡ含量下降、AT1受体及COX-2表达下调、cAMP含量升高、PKA表达上调。
Purpose
Water metabolism balance disorder is one of the most common clinical Symptoms of chronic renal failure,often occur at an early stage of CRF.As one of important risk factors,it can cause rapid deterioration of renal function.To rectify timely water metabolism balance disorder,can improve renal function and delay progression of CRF.It has great significance to improve quality of life in patients with CRF.At present,the basic pathogenesis of CRF according to Traditional Chinese Medicine theories was considered to be kidney-yang deficiency.At Early and medium-term of CRF,warm and tonify kidney-yang therapy acquired a better effect in CRF treatment.In this study,we set up the rats model of chronic renal failure with kidney-yang deficiency,to observe renal AQP2 expression changes, changes of angiotensinⅡand cyclic adenosine monophosphate contents in rat renal tissue, and expression changes of angiotensinⅡtype 1 receptor,cyclooxygenase-2 and protein kinase A,by using biology and morphology technique.Order to explore the Pharmacological treatment mechanism of yougui pill in disorder of water metabolism of CRF,and to provide experimental evidence for pathophysiological mechanisms of "obstruction of qi activities" of Kidney-Yang Deficiency.
Methods
1.Setting up Model and Administration
Thirty Healthy male wistar rats were randomized into normal group,model group,yougui pill group and telmisartan group.From frist day of experiment,rats of model group,yougui pill group and telmisartan group were given by 200mg/Kg/d adenine ig daily morning,the normal control group rats were intragastrically administrated with distilled water of corresponding volume,totally for 21 days.After two weeks adenine ig,rats of yougui pill group and telmisartan group were given with yougui pill(at 3.6g/kg/d) and telmisartan(at 5.4mg/Kg/d) Separately by gastric irrigation daily afternoon,rats of normal control group and model group were intragastrically administrated with distilled water of corresponding volume,,totally for 21 days.
2.Indexes were detected.:
In experimental process,to observe changes of behavior,average weight,Urine volumes and urine specific gravity,blood Scr and BUN content,renal tissue pathological of rats;Expression of renal tissue AQP2 was detected by immtmohistochemistry method and Western blot analysis;;Blood AVP content,renal tissue angiotensinⅡand cyclic adenosine monophosphate content were determined by radioimmunoassay;Renal tissue Protein kinase A expression was detected by immunohistochemistry method;Renal tissue angiotensinⅡtype 1 receptor and cyclooxygenase-2 were determined by Western blot analysis.
3.Statistical data analysis
The data were expressed as(?)±SD.Completely randomized design one-way ANOVA was used to deal with data by SPSS10.0 statistical software,P＜0.05 for significantly difference.
Results
1.Impact of Yougui Pill on renal function of chronic renal failure rats with kidney-yang deficiency.
The experimental results show that model group rats appeared intolerance to cold,cold four limbs,loss of appetite,weight loss,less activity.Compared with the normal group,model group rats show a marked increase in urine volume,decreased urine specific gravity,increase of blood Scr and BUN content significantly(P＜0.05) and Renal tissue by light microscopy observation shows glomerular expand cysts,interstitial fibrosis and a large amount of inflammatory cell infiltration,tubular compensatory enlargement.Compared with model group,Yougui Pill group rats show better feeding,stronger activity,more shiny hair,pretty sencitive reaction,body weight increasing,urine volume decreased,urine specific gravity increased,Scr and BUN content in blood decreased(P＜0.05),.Renal tissue pathological injury relieved
2.Influence of yougui pill on the expression of renal tissue AQP2 of rats of chronic renal failure with kidney-yang deficiency.
In immunohistochemical detection,Compared with the normal group,AQP2 expression of model group rats in principal cell membrane and cytoplasm of kidney connecting duct decreased.It manifested as brown particles reducing significantly and slight loss of color in principal cell membrane and cytoplasm.Imaging analysis showed integrated optical density(IOD) of AQP2 immunoreactivity positive in renal collecting tubular epithelial cells was significantly lower than that in normal group rats(P＜0.05);Compared with model group, AQP2 expression of yougui pill group rats in principal cell membrane and cytoplasm of kidney connecting duct increased.It presented as brown particles increasing significantly and darker in color in principal cell membrane and cytoplasm.Imaging analysis showed integrated optical density(IOD) of AQP2 immunoreactivity positive in renal collecting tubular epithelial cells was significantly higher than that in model group rats(P＜0.05 ).Western blot proved that AQP2 expression of renal tissue decreased obviously in model group rats.Gray scales was determined with image analysis system.Compared with normal group,gray scales of renal tissue AQP2 expression decreased in model group rats(P＜0.05).Compared with model group,AQP2 expression of renal tissue increased obviously in yougui pill group rats with western blot,gray scales of renal tissue AQP2 expression was higher in yougui pill group rats than that in model group(P＜0.05).
3.Influence of yougui pill on Contents of blood AVP,angiotensinⅡand cyclic adenosine monophosphate in renal tissue,expression of renal tissue angiotensinⅡtype 1 receptor etc of chronic renal failure rats with kidney-yang deficiency.
The results show that blood AVP content of three groups rats was no significant difference(P＞0.05).Compared with the normal group,content of angiotensinⅡ,the expression of angiotensinⅡtype 1 receptor and cyclooxygenase-2 in renal tissue were elevated significantly.cyclic adenosine monophosphate content and expression of protein kinase A of renal tissue were significantly decreased in model group rats(P＜0.05);Compared with the model group,Content of angiotensinⅡ,the expression of angiotensinⅡtype 1 receptor and cyclooxygenase-2 in renal tissue were decreased significantly,cyclic adenosine monophosphate content and expression of protein kinase A of renal tissue were significantly increased in yougui pill group rats(P＜0.05).
The results showed that one of the mechanisms of water metabolism balance disorder of chronic renal failure is probably reduced AQP2 expression of renal collecting duct.The theory of Chinese medical considered kidney goveming water..It mainly manifested in maintaining the balance of the body water metabolism.During kidney yang deficiency,it will occur obstruction of qi activities and result in disturbance of water metabolism.The experimental results indicate that one of the essence of obstruction of qi activities is AQP2 expression decreased.The possible mechanism of AQP2 expression decreased in renal tissue is due to that increased angiotensinⅡcontent in renal tissue,increased angiotensinⅡtype 1 receptor and cyclooxygenase-2 expression,This results in renal tissue content of cyclic adenosine monophosphate and protein kinase A expression decreased,making the expression of AQP2 in the kidney decreased.After Warmly Nourishing Kidney-yang treatment with Yougui Pill,angiotensinⅡcontent in renal tissue was decreased,expression of angiotensinⅡtype 1 receptor and cyclooxygenase-2 in renal tissue was decreased and cyclic adenosine monophosphate content and expression of protein kinase A increased.It results in increased renal expression of AQP2,which corrects water metabolic disorder in chronic renal failure, improves renal function,delay the progress of chronic renal failure..
Conclusion:
1.Chronic renal failure rats with kidney-yang deficiency have a marked increase in urine volume,decreased specific gravity,increase of blood Scr and BUN content and renal tissue pathological injury significantly,treatment with Yougui Pill can improve above facts apparently.
2.AQP2 expression of renal tissue of Chronic renal failure rats with kidney-yang deficiency decreased.After treatment with Yougui Pill,AQP2 expression of renal tissue increased.
3.Yougui pill have no apparent effects on blood AVP content.of Chronic renal failure rats with kidney-yang deficiency
4.Chronic renal failure rats with kidney-yang deficiency show that AngiotensinⅡcontent and expression of angiotensinⅡtype 1 receptor and cyclooxygenase-2 in renal tissue were increased,cyclic adenosine monophosphate content and expression of protein kinase A decreased.
5.After treatment with Yougui Pill,AngiotensinⅡcontent and expression of angiotensinⅡtype 1 receptor and cyclooxygenase-2 in renal tissue were decreased,cyclic adenosine monophosphate content and expression of protein kinase A increased.
水代谢平衡紊乱是慢性肾功能衰竭(CRF)最常见的临床表现之一,往往在CRF早期就出现,是能够导致肾功能急剧恶化的重要危险因素。因此及时纠正CRF早期水代谢平衡紊乱,对改善肾功能,延缓CRF病程进展,提高患者生存质量,具有重要意义。中医认为CRF基本病机属于肾阳虚,临床上采用温补肾阳方法治疗CRF也取得了较好的效果,但机理尚未阐明。本研究以分子生物学、形态学等检测技术,观察了温补肾阳传统名方右归丸对肾阳虚型慢性肾衰模型大鼠肾组织AQP2表达的影响,以及对血中AVP水平、肾组织中血管紧张素Ⅱ(AⅡ)水平、环磷酸腺苷(cAMP)水平、肾组织中血管紧张素ⅡAT1受体(AT1R)表达、环氧合酶2(COX-2)表达、蛋白激酶A(PKA)表达的影响,旨在从分子水平探讨右归丸治疗慢性肾衰水液代谢平衡紊乱的药理作用机制,并为肾阳虚证“气化不利”的病理生理学机制提供实验依据。
方法
1.动物造模及给药
健康雄性Wistar大鼠随机分为对照组、模型组、右归丸组及替米沙坦组。模型组、右归丸组及替米沙坦组大鼠每日上午按200mg/kg/d给予2%的腺嘌呤混悬液灌服,建立肾阳虚型慢性肾衰大鼠模型,对照组大鼠给予相应量蒸馏水灌胃,连续21天。从造模的第3周开始,右归丸组及替米沙坦组大鼠每日上午灌服腺嘌呤的同时,开始每日下午分别灌服右归丸(按3.6 g/kg/d)及替米沙坦(按5.4mg/Kg/d),对照组及模型组大鼠给予相应量蒸馏水灌胃,连续21天。
2.指标观察
实验过程中,观察大鼠的一般状态、体重、尿量、尿比重、血Scr、BUN含量及肾组织病理形态的变化;采用免疫组化及Western blot方法测定大鼠肾组织AQP2表达;采用放射性免疫方法检测大鼠血AVP含量、肾组织AⅡ及cAMP含量;采用免疫组化方法检测肾组织PKA表达;利用Western blot方法测定大鼠肾组织AT1受体、COX-2蛋白表达,
3.统计学处理
计量资料用(?)±SD表示,采用SPSS10.0统计学软件进行ANOVA(完全随机设计的单因素方差分析)统计方法处理,以P＜0.05为有显著性差异。
结果
1.右归丸对肾阳虚型慢性肾衰大鼠肾功能影响
结果显示,模型组大鼠出现畏寒肢冷、食量减少、体重下降、活动减少;与对照组比较,尿量明显增加,尿比重下降,血Scr及BUN含量显著增高(P＜0.05),肾组织光镜观察可见肾小球囊腔扩大,间质纤维组织增生及大量炎细胞浸润,肾小管呈代偿性扩张。与模型组比较,右归丸组大鼠摄食较好、活动力较强、被毛较光泽、反应灵敏、体重均有不同程度增加,尿量减少、尿比重增加、血Scr及BUN含量下降(P＜0.05)、肾组织光镜观察可见病理损伤明显减轻。
2.右归丸对肾阳虚型慢性肾衰大鼠肾组织AQP2表达影响
免疫组化方法检测表明:模型组大鼠肾脏集合管上皮细胞胞膜胞浆AQP2的表达较对照组明显减弱,表现为细胞胞膜和胞浆棕黄色颗粒明显减少,颜色明显变浅,图像分析表明:模型组大鼠肾脏集合管上皮细胞AQP2阳性表达累积光密度值明显低于对照组(P＜0.05);右归丸组大鼠肾脏集合管上皮细胞胞膜胞浆AQP2的表达较模型组明显增强,表现为细胞胞膜胞浆棕黄色颗粒明显增多,颜色明显加深,图像分析结果显示:右归丸组大鼠肾脏集合管上皮细胞AQP2阳性表达累积光密度值明显高于模型组(P＜0.05)。western blot方法检测显示:模型组大鼠肾组织AQP2表达下降,表现为条带窄,密度小,颜色浅。图像分析结果显示:模型组大鼠AQP2表达条带灰度值显著低于对照组;右归丸组大鼠肾组织AQP2蛋白表达增加,表现为条带宽,密度大,颜色深,图像分析结果显示:右归丸组大鼠。肾组织AQP2表达条带灰度值显著高于模型组(P＜0.05)。
3.右归丸对肾阳虚型慢性肾衰大鼠血中AVP含量、肾组织中AⅡ、cAMP含量、AT1R表达等影响。
结果表明,三组大鼠血中AVP含量无显著性差异(P＞0.05)。与对照组比较,模型组大鼠肾组织AⅡ含量、AT!R及COX-2表达明显升高、cAMP含量及PKA表达显著下降(P＜0.05);与模型组比较,右归丸组大鼠肾组织中AⅡ含量、AT!R及COX-2表达明显降低、cAMP含量及PKA表达增加(P＜0.05)。
结果显示,慢性肾衰发生水代谢平衡紊乱的可能机制之一为肾脏集合管AQP2表达下降。中医理论的肾主水功能,主要体现在依靠肾的气化作用“升清降浊”以维持机体水液的动态平衡,当肾阳虚气化功能减退时则出现水液代谢障碍。由此推测:肾脏的气化功能减退的实质之一,可能通过AQP2表达的下调,影响了肾脏的重吸收功能。而肾组织AQP2表达下降的可能机制为,通过肾组织中AⅡ含量升高、AT1R及COX-2表达增加,导致肾组织中cAMP含量及PKA表达降低,使AQP2在肾脏的表达下降;采用右归丸治疗,通过温补肾阳,使肾组织中AⅡ含量、AT1R及COX-2表达降低,增加肾组织中cAMP含量及PKA表达,导致肾脏AQP2的表达增加,改善慢性肾衰水代谢平衡紊乱,保护肾功能,延缓慢性肾衰进展。
结论
1.肾阳虚型慢性肾衰模型大鼠尿量增加,尿比重降低;血Scr及BUN水平增加;肾组织病理可见明显损伤;右归丸治疗能够明显改善上述病理变化。
2.肾阳虚型慢性肾衰模型大鼠肾组织AQP2表达下调;右归丸治疗可使AQP2表达上调。
3.右归丸对肾阳虚型慢性肾衰模型大鼠血AVP含量无显著影响。
4.肾阳虚型慢性肾衰大鼠模型肾组织中AⅡ含量升高、AT1受体及COX-2表达上调、cAMP含量下降、PKA表达下调。
5.右归丸使肾组织中AⅡ含量下降、AT1受体及COX-2表达下调、cAMP含量升高、PKA表达上调。
Purpose
Water metabolism balance disorder is one of the most common clinical Symptoms of chronic renal failure,often occur at an early stage of CRF.As one of important risk factors,it can cause rapid deterioration of renal function.To rectify timely water metabolism balance disorder,can improve renal function and delay progression of CRF.It has great significance to improve quality of life in patients with CRF.At present,the basic pathogenesis of CRF according to Traditional Chinese Medicine theories was considered to be kidney-yang deficiency.At Early and medium-term of CRF,warm and tonify kidney-yang therapy acquired a better effect in CRF treatment.In this study,we set up the rats model of chronic renal failure with kidney-yang deficiency,to observe renal AQP2 expression changes, changes of angiotensinⅡand cyclic adenosine monophosphate contents in rat renal tissue, and expression changes of angiotensinⅡtype 1 receptor,cyclooxygenase-2 and protein kinase A,by using biology and morphology technique.Order to explore the Pharmacological treatment mechanism of yougui pill in disorder of water metabolism of CRF,and to provide experimental evidence for pathophysiological mechanisms of "obstruction of qi activities" of Kidney-Yang Deficiency.
Methods
1.Setting up Model and Administration
Thirty Healthy male wistar rats were randomized into normal group,model group,yougui pill group and telmisartan group.From frist day of experiment,rats of model group,yougui pill group and telmisartan group were given by 200mg/Kg/d adenine ig daily morning,the normal control group rats were intragastrically administrated with distilled water of corresponding volume,totally for 21 days.After two weeks adenine ig,rats of yougui pill group and telmisartan group were given with yougui pill(at 3.6g/kg/d) and telmisartan(at 5.4mg/Kg/d) Separately by gastric irrigation daily afternoon,rats of normal control group and model group were intragastrically administrated with distilled water of corresponding volume,,totally for 21 days.
2.Indexes were detected.:
In experimental process,to observe changes of behavior,average weight,Urine volumes and urine specific gravity,blood Scr and BUN content,renal tissue pathological of rats;Expression of renal tissue AQP2 was detected by immtmohistochemistry method and Western blot analysis;;Blood AVP content,renal tissue angiotensinⅡand cyclic adenosine monophosphate content were determined by radioimmunoassay;Renal tissue Protein kinase A expression was detected by immunohistochemistry method;Renal tissue angiotensinⅡtype 1 receptor and cyclooxygenase-2 were determined by Western blot analysis.
3.Statistical data analysis
The data were expressed as(?)±SD.Completely randomized design one-way ANOVA was used to deal with data by SPSS10.0 statistical software,P＜0.05 for significantly difference.
Results
1.Impact of Yougui Pill on renal function of chronic renal failure rats with kidney-yang deficiency.
The experimental results show that model group rats appeared intolerance to cold,cold four limbs,loss of appetite,weight loss,less activity.Compared with the normal group,model group rats show a marked increase in urine volume,decreased urine specific gravity,increase of blood Scr and BUN content significantly(P＜0.05) and Renal tissue by light microscopy observation shows glomerular expand cysts,interstitial fibrosis and a large amount of inflammatory cell infiltration,tubular compensatory enlargement.Compared with model group,Yougui Pill group rats show better feeding,stronger activity,more shiny hair,pretty sencitive reaction,body weight increasing,urine volume decreased,urine specific gravity increased,Scr and BUN content in blood decreased(P＜0.05),.Renal tissue pathological injury relieved
2.Influence of yougui pill on the expression of renal tissue AQP2 of rats of chronic renal failure with kidney-yang deficiency.
In immunohistochemical detection,Compared with the normal group,AQP2 expression of model group rats in principal cell membrane and cytoplasm of kidney connecting duct decreased.It manifested as brown particles reducing significantly and slight loss of color in principal cell membrane and cytoplasm.Imaging analysis showed integrated optical density(IOD) of AQP2 immunoreactivity positive in renal collecting tubular epithelial cells was significantly lower than that in normal group rats(P＜0.05);Compared with model group, AQP2 expression of yougui pill group rats in principal cell membrane and cytoplasm of kidney connecting duct increased.It presented as brown particles increasing significantly and darker in color in principal cell membrane and cytoplasm.Imaging analysis showed integrated optical density(IOD) of AQP2 immunoreactivity positive in renal collecting tubular epithelial cells was significantly higher than that in model group rats(P＜0.05 ).Western blot proved that AQP2 expression of renal tissue decreased obviously in model group rats.Gray scales was determined with image analysis system.Compared with normal group,gray scales of renal tissue AQP2 expression decreased in model group rats(P＜0.05).Compared with model group,AQP2 expression of renal tissue increased obviously in yougui pill group rats with western blot,gray scales of renal tissue AQP2 expression was higher in yougui pill group rats than that in model group(P＜0.05).
3.Influence of yougui pill on Contents of blood AVP,angiotensinⅡand cyclic adenosine monophosphate in renal tissue,expression of renal tissue angiotensinⅡtype 1 receptor etc of chronic renal failure rats with kidney-yang deficiency.
The results show that blood AVP content of three groups rats was no significant difference(P＞0.05).Compared with the normal group,content of angiotensinⅡ,the expression of angiotensinⅡtype 1 receptor and cyclooxygenase-2 in renal tissue were elevated significantly.cyclic adenosine monophosphate content and expression of protein kinase A of renal tissue were significantly decreased in model group rats(P＜0.05);Compared with the model group,Content of angiotensinⅡ,the expression of angiotensinⅡtype 1 receptor and cyclooxygenase-2 in renal tissue were decreased significantly,cyclic adenosine monophosphate content and expression of protein kinase A of renal tissue were significantly increased in yougui pill group rats(P＜0.05).
The results showed that one of the mechanisms of water metabolism balance disorder of chronic renal failure is probably reduced AQP2 expression of renal collecting duct.The theory of Chinese medical considered kidney goveming water..It mainly manifested in maintaining the balance of the body water metabolism.During kidney yang deficiency,it will occur obstruction of qi activities and result in disturbance of water metabolism.The experimental results indicate that one of the essence of obstruction of qi activities is AQP2 expression decreased.The possible mechanism of AQP2 expression decreased in renal tissue is due to that increased angiotensinⅡcontent in renal tissue,increased angiotensinⅡtype 1 receptor and cyclooxygenase-2 expression,This results in renal tissue content of cyclic adenosine monophosphate and protein kinase A expression decreased,making the expression of AQP2 in the kidney decreased.After Warmly Nourishing Kidney-yang treatment with Yougui Pill,angiotensinⅡcontent in renal tissue was decreased,expression of angiotensinⅡtype 1 receptor and cyclooxygenase-2 in renal tissue was decreased and cyclic adenosine monophosphate content and expression of protein kinase A increased.It results in increased renal expression of AQP2,which corrects water metabolic disorder in chronic renal failure, improves renal function,delay the progress of chronic renal failure..
Conclusion:
1.Chronic renal failure rats with kidney-yang deficiency have a marked increase in urine volume,decreased specific gravity,increase of blood Scr and BUN content and renal tissue pathological injury significantly,treatment with Yougui Pill can improve above facts apparently.
2.AQP2 expression of renal tissue of Chronic renal failure rats with kidney-yang deficiency decreased.After treatment with Yougui Pill,AQP2 expression of renal tissue increased.
3.Yougui pill have no apparent effects on blood AVP content.of Chronic renal failure rats with kidney-yang deficiency
4.Chronic renal failure rats with kidney-yang deficiency show that AngiotensinⅡcontent and expression of angiotensinⅡtype 1 receptor and cyclooxygenase-2 in renal tissue were increased,cyclic adenosine monophosphate content and expression of protein kinase A decreased.
5.After treatment with Yougui Pill,AngiotensinⅡcontent and expression of angiotensinⅡtype 1 receptor and cyclooxygenase-2 in renal tissue were decreased,cyclic adenosine monophosphate content and expression of protein kinase A increased.
引文
[1]叶任高,沈清瑞.肾脏病诊断与治疗学.北京:人民卫生出版社,1994:517-522
[2]叶任高,阳晓.论慢性肾功能衰竭的进展机制和对策.中国医刊.2001,36(3):2-4.。
[3]Brenner BM,Meyer TW,Hostetter TH.Dietary protein and the progressive nature of kidney disease:The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging,renal ablation,and intrinsic renal disease.N Engl J Meal.1982,307(11):652-659.
[4]Schrier RW,Harris DCH,Chan L,et al.Tubular Hypermetabolism as a factor in the progression of chronic renal failure.Am J Kidney Dis.1988,12(3):243-249.
[5]王海燕.肾脏病学(第二版).北京:人民卫生出版社,1996:1385-426.
[6]张道友,孙亚南.慢性肾功能衰竭患者血脂质变化.中国动脉硬化杂志.1998,6(3):249-250.
[7]邹洪斌,王印全,崔明姬,等.老年肾脏疾病血清脂质水平的研究.中国老年学杂志.1999,19(3):158-159.
[8]上海市肾脏病心血管并发症调查协作组.上海地区透析患者血脂改变的调查.中华肾脏病杂志.2001,17(2):101-104.
[9]王云增,庄一义,汪俊军,等.慢性肾衰透析患者胆固醇酯转运蛋白及血脂变化.上海医学检验杂志.2000,15(1):39-41.
[10]安惠霞,刘素雁,任野平.血液透析对慢性肾功能衰竭患者血清脂质代谢的影响.哈尔滨医科大学学报.2001,35(6):438-439.
[11]樊均明,许国章.终末期肾功能不全患者高血压与血脂、脂蛋白和载脂蛋白的关系.临床内科杂志.1996,13(3):35-36.
[12]黄效维,麦慈光,梁波.慢性肾脏病患者血载脂蛋白AI的变化.安徽医学.2002,23(5):21-23.
[13]De-Gomez-Dumm NT,Giammona AM,Touceda LA,et al.Lipid abnormalities in chronic renal failure patients undergoing hemodiaiysis.Medicina-(B-Aires).2001,61(2):14-26.
[14]陈莉芬,李荣亨.肿瘤坏死因子在肾脏疾病中的研究进展.国外医学泌尿系统分册.2001,21(4):147-149.
[15]尹力.肾小管上皮细胞产生的细胞因子在肾间质纤维化中的作用.肾脏病与透析肾移植杂志.1994,3(4):309-311.
[16]李玲,邹万忠.肾小管和肿瘤坏死因子与间质纤维化的关系.肾脏病与透析肾移植杂志.1998,7(4):318-320
[17]吴华,许福照.内皮素与肾脏疾病.国外医学.泌尿系统分册.1994,14(6):250-253
[18]Pariclo N,R emuzzi G.Role of andothen in Glomerrular jnjury.Kidney Int,1993,43(39):576.
[19]Bruchu E,Lacasse S.Noreau C,et al.Endothelin ET(A) receptor blockade pevents the progression of renal falure and nypertension in uraemic rats.Nephrol Dial Transplant.1999,14(8):1881-1888.
[20]张晓蜂,王小春.慢性肾功能衰竭血浆内皮素含量变化.中华肾脏病杂志。1996,12(1):46.
[21]Yuqiang Ge,Dowahn Ahn,et al.Collecting duct-specific knockout of endothelin-1 alters vasopressin regulation of urine osmolality.Am J Physiol Renal Physiol.2005,288:F912.
[22].Mezzano SA,Ruiz-Ortega M,Egjdo J.Angiotensin II And Renal Fibrosis HyPertension .2001.38:635-638.
[23]Ruiz-ortega M,RuPerez M,Lorenzo O,et al.Angiotensin Ⅱ regulates the synthesis of Porinflammatory Cytokines and Chemokines in the kidney.Kidney Int.2002.62(supp182):S12-S22.
[24]林善锬,吴永贵.肾素-血管紧张素系统与肾脏疾病.中国实用内科杂志.1998,18(12):759-762.
[25]Suzuki Y,Ruiz-Ortega M,Lorenzo O.Inflammation and angiotensin Ⅱ.Int J Biochem Cell Biol.2003,35:881-900.
[26]Sttkru Oguzkan Topcu,Michael Pedersen,Rikke Nφrregaard,et al.Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction.Am J Physiol Renal Physiol.2007,292:F736-F748,
[27]Edwards RM,Stack EJ.Angiotensin Ⅱ inhibits glomerular adenylate cyclase via the angiotensin Ⅱ receptor subtype 1(AT1).J Pharmacol Exp Ther.1993,266(2):506-510,.
[28]Feria I,Pichardo I,Juarez P,et al.Therapeutic benefit ofspironolactone in experimental chronic cyclosporine Anephrotoxicity.Kidney Int.2003,63(1):43-52.
[29]Juknevicius I,Segal Y,Kren S,et al.Aldosterone causes TGF-8 expression(abstract).J Am Soc Nephrol.2000,11(3):622-627.
[30]Blasi ER,Rosenberg R,Rudolph AE,et al.Aldosterone/saltinduces renal inflammation and fibrosis in hypoertensive rats.Kidney Int.2003,63(5):1791-1800.
[31]李晓东,郭志军,高山林,等.醛固酮对肾小球系膜细胞合成分泌纤维连接蛋白的影响.山西医药杂志.2006,35(5):381-383.
[34]Cheng HF,Wang C J,Moeckel GW,et al.Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension.Kidney Int.2002,62(3)929-939.
[35]Wang JL,Cheng HF,Zhang MZ,et al.Selective increase of cyclooxygenase-2 expression in a model of renal ablation.Am J Physiol.1998,275(4 Pt 2):613-622.
[36]Wang JL,Cheng HF,Shappell S,et al.A selective cyclooxygenase-2 inhibition decrease proteinuria and retards progressive renal injury in rats.Kidney Int.2000,57(6):2334-2342.
[37]Miyajima A,Ito K,Asano T,et al.Does cyclooxygenase-2 inhibitor prevent renal tissue damage in unilateral ureteral obstruction.J Urol.2001,166(3):1124-1129.
[38]Norregaard R,Jensen BL,Li C,et al.COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction.Am J Physiol Renal Physiol.2005,289(2):F322-F333.
[39]王少华,张晶瑜,王彬.试论慢性肾功能衰竭正虚邪实之病机.上海中医药大学学报.2004,18(2):31-32.
[40]王永钧.肾功能衰竭的中医认识及对策.浙江中医杂志,1993,(1):49.
[41]屠立茵,何立群.慢性肾衰的中医辨证分型与治疗.中国医刊.2001,63(6):55-56.
[42]叶传蕙.中医药治疗慢性肾功能衰竭思路与方法.中国临床医生.2002,30(1):51-53
[43]傅文录.慢性肾衰中医多级辨治思路与方法探讨,新中医.1999,31(6):3-5.
[44]远方,叶任高.叶任高治疗慢性肾功能衰蝎经验集药.辽宁中医杂志.2001,28(6):336-337.
[45]江志勤.郑平东治疗慢性肾功能衰竭经验.安徽中医临床杂志.2001,13(6):458.
[46]焦安钦.慢性肾衰蝎病机特点与治疗对策.山东中医药大学学报.2001,25(3):290.
[47]张慧.皮持衡教授诊治慢性肾衰竭的临床经验,中国中西医结合肾病杂志.2004,5(2):68-71.
[48]孔庆欲.陆鸿滨教授辨证治疗慢性肾衰竭的经验.中国中西医结合肾病杂志2003,(7)375-376.
[49]吴金秀.慢性肾功能不全失代偿的可逆因素探讨.中国医学工程,2006,14(2):219-220.
[50]黄继义,张燕林,李弋南.慢性肾功能衰竭危险因素分析及防治措施探讨.福建医科人学学报,2004,38(1):94-95.
[51]常笑雪,黄鹂.水通道蛋白在肾脏的表达及意义.河南科技大学学报(医学版),2004,22(3):236-238
[52]Yang B,Song Y,Zhao D,et al.Phenotype analysis of aquaporin28 nullmice.AmJ Physiol Cell Physiol,2005,288(5):C116-C170
[53]Yakata K,Hiroaki Y,Ishibashi K,et al.Aquaporin-11 containing a divergent NPA motif has normal water channel activit-y.Biochim Biophys Acta,2007,1768(3):688-693.
[54]Moris hita Y,Matsuzaki T,Hara-chikuma M,et al.Disruption of aquaporin-11 produces polycystic kidneys following vacuolization of the proximal tubule.Mol Cell Biol,2005,25(17):7770-7779.
[55]Lee J,Yoo K S,Kang D Q,et al.Gentamicin decreases the abun 2 dance of aquaporin water channels in rat kidey.Jpn J Pharmacol,2001,85(4):391-398
[56]Apostol E,Ecelbarger C A,Terris J,et al.Reduced renal medullary water channel expression in puromycin aminonu 2 cleoside 2 induced nephrotic syndrome.J Am Soc Nephrol,1997,8(1):15-24.
[57]韩婷,胡同杰,耿姗姗,等.低钠低磷型蛋白质制剂改善慢性肾功能衰竭患者营养状况的效果.中国营养杂志,2005,13(4):238-241.
[58]崔明,欧阳淑娟.慢性肾功能衰竭患者重组人红细胞生成素疗效观察.医学临床研究,2005,8,1172-1173.
[59]张萍,梁劲松.大剂量促红细胞生成素治疗肾性贫血的疗效观察.中国药房.2005,16(13):1009-1010.
[60]Mallwhe HH,Mawad H.Management of hyperpba Omtaenia of chreic kidney diseus lessons from the past and fut ure directione.Nephrol Dial Transphant.2002,17(7):1170-1175。
[61]Hervm J G,Pmdm D,Cemzo S.Treannerrt of hyperphos phatenua wit h ovelwrer hydmddmide in hemodidysis pulienla:Acomparism wit h calcium acetate.Kidney Int Suppl.2003,(85):69-721
[62]陈莉,刘英.中西医结合治疗慢性肾功能不全疗效观察.辽宁中医杂志.2006,33(7):852-853.
[63]付平,周莉等.氯沙坦治疗慢性肾功能不全合并高尿酸血症的疗效观察.中国全科医学.2004,7(24):1854-1855.
[64]Cross J.Endothelial dysfunction in uraemia.Blood Punif.2002,20(5):456-459.
[65]伍锦泉,潘志铣,陈玉平,等.探讨氧化应激和炎症反应在慢性肾功能衰竭(CRF)患者内皮功能失调和动脉粥样硬化中的作用.中国基层医药.2006,13(4):641-642.
[66]Sorensenke,celermajer DS,Georgakopoulos,et al,Impairment of endot heliumdependent dilation is an early event in children with familial hypercholesterolemia and is related to lipoprotein(a)level.Chin Invest.1994,93(1):50-55.
[67]丁品,李健.血管内皮功能障碍与冠脉疾病关系及防治进展.中国全科医学.2005,8(23):1977-1978.
[68]朱冬菊,张玲.慢性肾衰竭的抗氧化治疗.中国血液透析.2006,5(2):91-941
[69]康宁,高慧,李岩,位东卫.右归丸在血液透析患者中的临床应用.医药世界.2006,(9):123.
[70]王济生.慢性肾衰竭中医治疗探讨山东中医杂志.2004,23(12):709-711.
[71]张金华,万亮瑜.中医治疗慢性肾功能衰竭体会.中华现代中医学杂志.2006,2(8):706-707.
[72]栾洪文,王天祥,马彩霞.中医治疗慢性肾功能衰竭的几种方法.中国临床医药研究杂志.2003,92:9140.
[73]肖相如.温阳法在慢性肾衰中的运用。北京中医药大学学报.2005,28(5):86-87.
[74]杨应兄,孙红旭,薛国忠.戴恩来老师治疗慢性肾功能衰竭经验.甘肃中医.2007,20(3):8-9
[75]傅晓骏,张慧嫦,刘瑾.肾毒宁治疗慢性肾衰竭62例临床研究.中国中西医结合肾病杂志.2004,5(10):607-608.
[76]廖竹芬.复方丹参注射液合温阳通利方治疗慢性肾衰30例.中国中医药科技.2006,13(4):276.
[77]廖竹芬.复方丹参注射液合温阳通利方治疗慢性肾衰30例疗效观察.新中医.2005,37(4):54-55.
[78]王身菊,朱成英.益气养阴和络泄浊法治疗慢性肾功能衰竭46例疗效观察.新中医.2003,35(4):18-20.
[79]何灵芝,李学铭.补阳还五汤治疗肾病举隅.广西中医药.2005,28(6):34.
[80]易晓颖,陈彤,舒惠荃.中西医结合治疗慢性肾衰的临床观察.成都中医药大学学报,2000,23(4):49-50.
[81]沈维增,谢峥伟,吕红梅.温阳利水、化瘀泄浊法延缓慢性肾功能衰竭进展临床研究.中国中医药信息杂志.2007,14(4):17-18.
[82]王皓.肾宁康对肾衰大鼠肾组织丙二醛等指标的影响.辽宁中医杂志2005,32(4):373-374.
[83]吴佳武.温阳清浊汤治疗慢性肾功能衰竭临床观察.湖北中医学院学报.2007,9(4):47.
[84]段淑兰,陈小仙,蒋鹏.中药为主治疗慢性肾功能不全40例临床观察.河南中医.2004,5(24):36-37
[85]王暴魁,张军,刘震等.温脾清化汤治疗慢性肾功能不全的临床观察.中国医药学报.2003,18(6):341-343.
[86]来永兰,孙文芹,安良毅等.祛湿温阳汤灌肠治疗慢性肾功能不全临床察.中国中西医结合急救杂志.2003,10(4):247-248.
[87]周竹,李俊,周梅,等尿毒清颗粒治疗早中期慢性肾功能衰竭的临床观察.中华临床医药杂志.2001,2(11):21-23.
[88]史伟尿毒清冲剂治疗慢性肾衰竭的临床观察.中国中西医结合肾病杂志.2001,9(12):734-735.
[89]靖新文.肾毒清冲剂治疗慢性肾衰竭110例.山东中医药大学学报.2000,24(6):19.
[90]王怡,何立群,郑平东.抗纤灵冲剂改善慢性肾衰竭实验兔血液动力学及肾小球硬化的研究.上海中医药大学学报.2000,14(2):47-49.
[91]王济生,陈丽霞,元琦.肾康灵治疗慢性肾衰竭临床观察.山东中医药大学学报.2000,24(1):31-33.
[92]何立群,郑平东,朱燕俐,等.肾衰冲剂对慢性肾功能衰竭动物肾组织的影响.上海中医药大学学报.2000,14(2):50-51.
[93]王小琴,邵朝弟,谭大琦,等.肾安颗粒治疗慢性肾衰竭的临床观察.中国中西医结合肾病杂志.2003,4(7):393-395.
[94]阮诗伟,郑敏麟,陈建,等.益肾降浊冲剂治疗慢性肾衰竭的实验研究.中国中西医结合肾病杂志.2003,4(9):506-509.
[95]王志红.大黄治疗慢性肾功能衰竭172例疗效分析.中国综合临床.2005,21(4):332-333.
[96]周钦,曹文富,李荣亨.大剂量黄芪注射液对慢性肾功能不全患者血浆、尿液内皮素的 影响.中国中药杂志.2001,26(3):200-201.
[97]张颖,张士英,王微,等.黄芪注射液对慢性肾衰竭免疫功能的影响.长春中医学院学报.2000,16(2):28.
[98]刘杰,杜学海,傅芳婷,等.人参皂甙清除反应性氧代谢产物预防大鼠膜性肾病.肾脏病与透析肾移植杂志.1995,4(1):29-31
[99]杨俊伟,黎磊石.冬虫夏草与肾冷缺血-再灌注损伤的研究.肾脏病与透析肾移植杂志,1995,4(1):21..
[100]程庆珠,于力方,师锁柱,等.冬虫夏草对5/6肾切除大鼠肾脏病理改变的影响.中华肾脏病杂志.1994,10(1):30
[101]唐树德,王崇行,钱珠,等.首乌治疗早期肾脏损害血瘀型高血压患者28例.中国中西医结合杂志.1994,14(5):302-305.
[102]张国强,叶任高,孔庆瑜,等.丹参对狼疮性肾炎成纤维细胞增殖凋亡、及c-myc蛋白表达的影响[J].中国中西医结合杂志.1997,17(8):473-475.
[103]刘云苗.川芎嗪对慢性肾衰患者肾血流量和肌酐清除的影响.中国中西医结合杂志.1993,13(2):107
[104]杨学峰,杨海棠,张香勤.口服中药合灌肠泄浊加西医治疗慢性肾功能衰竭71例临床观察.四川中医.2003,21(2):23-24.
[105]韦明欣.大黄为主灌肠治疗慢性肾功能衰竭的疗效观察.广西医学.1995,17(5):4281.
[106]韩旭,陈美兰.中药保留灌肠治疗慢性肾功能衰竭58例临床观察.山西中医.1995,11(3):13.
[107]朱红云.治疗慢性肾功能衰竭42例临床观察.上海中医药杂志.1997,(5):23.
[108]李林芳,段淑云.改进中药保留灌肠法治疗慢性肾功能不全51例疗效观察.实用中西医结合临床.2006,6(6):57-58.
[109]张宇梅,王亚平,霍延红等.结肠透析治疗老年慢性肾功能衰竭的临床研究.实用诊断与治疗杂志.2007,21(12):888-889.
[110]王亚平,王志忠,李浩等.应用JS-308结肠透析机配合中药治疗慢性肾功能衰竭的临床研究.华北国防医药.2006,18(5):318-319.
[1]杜卉莲,傅晓晴.慢性肾衰动物的模型制备及临床应用.中医研究.2005,18(12):53-57.
[2]熊宁宁,董筱玉,何原惠,等.维护肾元中药治疗大白鼠慢性肾衰的实验研究.中华肾脏病杂志.1989,5(3):187-189.
[3]王耀光.肾皮质电灼所致慢性肾功能衰竭动物模型血癖初探.河南中医.1997,17(1)22-24.
[4]傅晓晴,林若勤,武一曼,等.腺嘌呤制作肾阳虚型慢性肾功能衰竭大鼠模型的生化研究,福建中医学院学报.2003,13(1):22-24.
[5]Wenning J J,Rennke G.Glomerular permeability and polyanion in Adriamycin nephrosis in the rat.Kidney Int.1983;24(2):152- 159.
[6]姜新酞,胡明昌.柔红霉素肾病:活性氧诱发脂质过氧化反应引起的肾组织损伤,中华肾脏病杂志.1991,7(2):74-76.
[7]王海燕.肾脏病学.北京:人民卫生出版社,1996,967-982.
[8]Barty M.Brenner.Brenner&Rector's The Kindey.北京:科学出版社,2001,1563-1585,1820-1868,1236.
[9]周静,爱民,王朝阳.腺嘌呤制作慢性肾功能衰竭大鼠疾病模型.内蒙古医学院学报.2004,26(4):248-252.
[10]赵海峰,张召峰.腺嘌呤制备大鼠慢性肾功能损伤的模型.癌变·畸变·突变.2008,20(5):376-379.
[11]肖相如.温阳法在慢性肾衰中的运用.北京中医药大学学报.2005,5(28):86-87.
[12]李佑生.温法治疗慢性肾衰研究进展.湖南中医学院学报.1992,12(2):59-62.]
[13]康宁,高慧,李岩,等.右归丸在血液透析患者中的临床应用.医药世界.2006,(9):123.
[14]王济生.慢性肾衰竭中医治疗探讨山东中医杂志.2004,23(12):709-711.
[15]张金华,万亮瑜.中医治疗慢性肾功能衰竭体会.中华现代中医学杂志.2006,2(8):706-707.
[16]申志强.慢性肾功能衰竭的水电解质紊乱其处理.中原医刊.1988,(2):44-47.
[17]阎祝三.慢性肾功能衰竭的非透析治疗.中国实用内科杂志.1998,18(6):332。
[18]Druere TB,Eckardtku KU,Frei U,et al.Does early anemiacorrection prevert complications of chronic renal failure.Clin Nephrol.1999,51(1):1 -11.
[19]黄继义,张燕林等.慢性肾功能衰竭危险因素分析及防治措施探讨.福建医科大学学报.2004,38(1):94-95..
[20]吴金秀.慢性肾功能不全失代偿的可逆因素探讨.中国医学工程.2006,14(2):219-220.
[21]刘鹏,陶汉华.肾气丸与右归丸补肾机理异同辨.河南中医.2008,28(4):67.
[22]焦淑芳,喻红.温阳通腑降浊法治疗慢性肾衰竭阳虚浊毒证疗效观察.湖南中医学院学报.2001.21(2):51-52.
[23]唐青.黄芪、附子等对慢性肾功能衰竭病人UA,HDLC的影响.中华名医论坛,2005,(2):58-59.
[24]韩家强,李仁善.温脾汤治疗慢性肾衰脾肾阳虚证对肾血流动力学的影响.黑龙江中医药.2001,(1):1.
[25]黄桂香.当归生物学效应研究.时珍国医国药.2001.12(3):262-263.
[26]穆守俊.中医药治疗慢性肾功能衰竭近况.河北中医.2001,23(2):155.
[27]黄黎明,梁恒,邢建宇.山茱萸提取物对慢性肾炎小鼠的药理作用及蛋白质组学效应的实验研究.中国药理学通报.2004,20(10):1144-50.
[28]熊玉兰,王金华,屠国瑞,等.熟地黄麦角甾苷对小鼠肾毒血清肾炎治疗作用的研究.世界科学技术.中医药现代化基础研究.2006,8(5):46-48
[1]杜卉莲,傅晓晴.慢性肾衰动物的模型制备及临床应用.中医研究.2005,18(12):53-57.
[2]Preston GM,Carroll TP,Guggino WB,et al.Appearance of water channels in xenops oocytes expressing red cell CHIP28 protein.Science.1992,256(5055):385-387.
[3]Kazuyoshi Muarta,Kaour Mitsuoka,Teurhisa Hiari,et ai.Structural determinants of water permeation through aquaporin-1.Nature.2000,407(6804):599-605.
[4]Haixin Sui,Bong Gyoon Han,John K Lee,et al.Structural basis of water specific transport through the AQP1 water channel. Nature.2001,414(6866):872-878.
[5]]Nielsen S, Frokiaer J, Marples D, et al. Aquaporins in the kidney: from molecules to medicine. Physiol. Rev 2002, 82(1):205-244.
[6]Eun Jin Sohn, Dae Gill Kang, Ho Sub Lee. Protective Effects of Glycyrrhizin on Gentamicin-Induced Acute Renal Failure in Rats.Pharmacology Toxicology. 2003, 93(3):116-122.
[7]Gong H, Wang WD, Tae Hwan K, et. al. Reduced renal expression of AQP2, P-AQP2 and AQP3 in haemorrhagic shock induced acute renal failure.Nephrol Dial Transplant. 2003, 18(12):2551-2559.
[8]Sabolic J, KatsuraY, Verbabatz JM, etal .The AQP2 water channel:effect of vasopressin treatment, microtubule disruption, and distribution in neonatal rats.J Member Biol. 1995,143(3):165-175.
[9]Knepper MA, Verbulif TG, Nielsen S. Role of aquaporins in water balance disorders.Curr Oprin Nephrol and Hyer.l997,6(4):367-371.
[10]Marples D,Frokiaer J,Dorup J,Knepper MA,et al.Hypokalemia induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Clin Invest. 1996,97(8): 1960-1968.
[11]Earm JH, Christensen BM, Frokiaer J, et al.Decreased aquaporin-2 expression and apical plasma membrane delivery in kidney collecting ducts of polyuric hypercalcemic rats. J Am Soc Nephrol.1998,9(12):2181-2193.
[12] Wang W, Li C, Kwon TH, et al. AQP3, p-AQP2,and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by CAMP-PDE inhibitors. Am J Physiol Renal Physiol.2002, 283(6): F1313-F1325.
[13]Marples D, Christensen S, Christensen EI, et al. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest. 1995, 95(4):1838-1845.
[14]Kwon TH, Frokiaer J, Fernandez-Llama P, et al. Reduced abundance of aquaporins in rats with bilateral ischemia-induced acute renal failure: prevention by alpha-MSH. Am J Physiol.1999,277(3 Pt 2):F413-F427.
[15]Apostol E,Ecelbarger CA,Terris J,et al.Reduced renal medullary water channel expression in puromycin aminonu-cleoside-induced nephrotic syndrome[J].J Am Soc Nephrol.1997,8(1):15-24.
[16]Tae-Hwan Kwon,Jφrgen Frφkiaer,Mark A.Knepper,et al.Reduced AQP1,-2,and -3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass Am J Physiol Renal Physiol,1998,275(5):F724-F741.
[17]Frokiaer J,Li C,Shi Y,et al.Renal aquaporins and sodium transporters with special focus on urinary tract obstruction.APMIS Suppl.2003,(109):71-79.
[18]Li C,Wang W,Kwon TH,et al.Downregulation of AQP 1,2,and 3 after ureteral obstruction is associated with a long-term urine-concentrating defect.Am J Physiol Renal Physiol.2001,281(1):F163-F171.
[19]Li C,Wang W,Knepper MA,et al.Downregulation of renal aquaporins in response to unilateral ureteral obstruction.Am J Physiol Renal Physiol.2003,284(5):F1066-F1079.
[20]Xu D,Yin X,Hui H,et al.Urinary excretion of aquaporin-2 channel protein in chronic heart failure rats.Chin Med J(Engl).2001,114(9):899-901.
[21]Asahina Y,Izumi N,Enomoto N,et al.Increased gene expression of water channel in cirrhotic rat kidneys.Hepatology.1995,21(1):169-173.
[22]Ohara M,Martin PY,Xu DL,et al.Upregulation of aquaporin 2 water channel expression in pregnant rats.J Clin Invest.1998,101(5):1076-1083.
[23]Deen PM,Verdijk MA,Knoers NV,et al.Requirement of human renal water channel aquaporin-2 for vasopressin-dependent conccntration of urine.Science.1994,264(5155):92-95.
[24]李屹,何立群.肾阳虚大鼠模型的水通道蛋白1改变.中西医结合学报.2008;6(5):498-501
[25]冼绍祥,欧明.肾阳虚型心力衰竭肾脏髓质水通蛋白的表达的实验研究.成都中医药大学学报.2007,30(2):39-41
[26]尧敏.济生肾气丸加减治疗中老年水肿100例.江苏中医药.2002,23(3):18.
[27]叶青补肾缩泉汤治疗老年男性夜尿增多24例.河北中医.2006,28(3):184.
[28]李凤辉金匮肾气丸合五苓散治疗尿崩症.山东中医杂志.2006,25(2):137-138.
[29]马步升,常景梅.中药治疗老年夜间多尿64例.广西中医药.1997,20(2):22.
[30]苟海峰.右归丸加减调治老年男性夜尿频数30例.辽宁中医学院学报.2004,6(4):103.
[31]陈旺全.妇女夜尿之治疗.台湾中医临床医学杂志.2007,13(2):114-116.
[32]陈素芝.同房遗尿治验.陕西中医.1994,15(6):272.
[1]杜卉莲,傅晓晴.慢性肾衰动物的模型制备及临床应用.中医研究.2005,18(12):53-57.
[2]]Nielsen S,Frokiaer J,Marples D,et al.Aquaporins in the kidney:from molecules to medicine.Physiol.Rev 2002,82(1):205-244.
[3]Knepper MA,Wade JB,Terris J,et al..Renal aquaporins.Kidney Int.1996,49(6):1712-1717.
[4]Brown D.The ins and outs of aquaporin-2 trafficking.Am J Physiol Renal Physiol.2003,284(5):F893-F901.
[5]Katsura T,Gustafson CE,Ausiello DA,et al.Protein kinase A phosphorylation is involved in regulated exoeytosis of aquaporin-2 in transfected LLC-PKI cells.Am J Physiol.1997,272(6 Pt 2):F817-F822.
[6]Brown D,Katsura T,Gustafson CE.Cellular mechanisms of aquaporin trafficking.Am J Physiol Renal Physiol.1998,27(3):328-331.
[7]Hasler U,Mordasini D,Bens M,et al.Long term regulation of aquaporin2 expression in vasopressin responsive renal collecting duct principal cells.J Biol Chem.2002,277(12):10379-10386.
[8]Knepper MA. Long-term regulation of urinary concentrating capacity. Am J Physiol.1998, 275(3 Pt 2):F332-F333.
[9]De Wardener HE, Herxheimer A. The effect of a high water intake on the kidney's ability to concentrate the urine in man. J Am Soc Nephrol.2000, 11(5):980-987.
[10]Lankford SP, Chou CL, Terada Y, et al. Regulation of collecting duct water permeability independent of cAMP-mediated AVP response.Am J Physioll.1991,261(3 Pt 2):F554- F566.
[11]DiGiovanni SR, Nielsen S, Christensen EI, et al. Regulation of collecting duct water channel expression by vasopressin in Brattleboro rat. Proc Natl Acad Sci U S A. 1994, 91(19):8984-8988.
[12]Nielsen S,Chou CL, Marples D, et al.Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci U S A. 1995, 92(4):1013-1017.
[13] Terns J, Ecelbarger CA, Nielsen S, et al. Long-term regulation of four renal aquaporins in rats. Am J Physiol.1996, 271(2 Pt 2):F414-F422.
[14]Ma T, Hasegawa H, Skach WR, et al. Expression, functional analysis, and in situ hybridization of a cloned rat kidney collecting duct water channel. Am J Physiol. 1994, 266(1 Pt 1):C189-C197.
[15]Yamamoto T, Sasaki S, Fushimi K, et al. Vasopressin increases AQP-CD water channel in apical membrane of collecting duct cells in Brattleboro rats. Am J Physiol. 1995, 268(6 Pt 1):C1546-C1551
[16]Jawadi, M. H., L. S. Ho, D. Dipette, et al. Ross.Regulation of plasma arginine vasopressin in patients with chronic renal failure maintained on hemodialysis. Am. J. Nephrol.1986,6(3):175-181.
[17]Bouby, N., S. Bachmann, D. Bichet, L. Bankir. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am. J. Physiol. 1990, 258 (4 Pt 2):F973-F979.
[18]Kwon, Tae-Hwan, J0rgen Fr(?)kiaer, et al. Reduced AQP1, -2, and -3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass.Am.J Physiol.1998,275(5 Pt 2):F724-F741.
[19]Michelle Boone,Peter M.T.Deen Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption.Pflugers Arch..2008,456(6):1005-1024.
[20]Kaschina E,Unger T.Angiotensin AT1/AT2 receptors:regulation,signalling and function[J].Blood Press.2003,12(2):70-88.
[21]Johnson RJ,Alpers CE,Yoshimura A,et al.Renal injury from angiotensin Ⅱ mediated hypertension.Hypertension.1992,19(5):464-474
[22]Satoh M,Kashihara N,Yamasaki Y,et al.Renal interstitial fibrosis is reduced in angiotensinⅡ type la receptor-deficient mice.J Am Soc Nephrol.2001,12(2):317-325
[23]Fern RJ,Yesko CM,Thornhill BA,et al.Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice.J Clin Invest.1999,103(1):3 9-46
[24]Mezzano SA,Ruiz-Omega M,Egido J.Angiotensin Ⅱ and Renal Fibrosis.Hypertension.2001,38:635-638.
[25]Jensen AM,Li C,Praetorius HA,et al.Angiotensin Ⅱ mediates downregulation of aquaporin water channels and key renal sodium transporters in response to urinary tract obstruction.Am J Physiol Renal Physiol.2006,291(5):F 1021-32.
[26]Kim E.J,Jung Y.W.,Kwon T.H.Angiotensin Ⅱ AT1 receptor blockade changes expression of renal sodium transporters in rats with chronic renal failure.J Korean Med Sci.2005,20(2):248-255.
[27]Sukru Oguzkan Topcu,Michael Pedersen,Rikke Nφrregaard,et al.Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction Am J Physiol Renal Physiol.2007,292(2):F736-F748.
[28]Edwards RM,Stack EJ.Angiotensin Ⅱ inhibits glomerular adenylate cyclase via the angiotensin Ⅱ receptor subtype 1(AT1).J Pharmacol Exp Ther.1993,266(2):506-510.
[29]刘敏,张桦,陈宏,等.血管紧张素Ⅱ对离体人胰岛细胞内游离Ca~(2+)及cAMP的影响.广东医学.2007,28(9):1395-1397.
[30]Ozturk H,Ozdemir E,Otcu S,et al.Renal effects on a solitary kidney of specific inhibition of cyclooxygenase-2 after 24 h of complete ureteric obstruction in rats.Urol Res.2002.30(4):223-226.
[31]Wang JL,Cheng HF,Zhang MZ,et al.Selective increase of cyclooxygenase-2 expression in a model of renal ablation.Am J Physiol.1998,275(4 Pt 2):F613-622.
[32]杨健,唐琳,刘章锁,等.罗非昔布对单侧输尿管梗阻大鼠肾间质纤维化的改善作用.郑州大学学报(医学版).2006,41(3):527-529.
[33]左怡沁,马骥,顾勇,等.环氧合酶在单输尿管梗阻大肾脏的表达.上海医学.2002,25(5):285。
[34]Ricardo SD,Ding G,Eufemio M,et al.Antioxidant expression in experimental hydronephrosis:role of mechanical stretch and growth factors.Am J Physiol Renal Physiol.1997,272(6 Pt 2):F789-F798.
[35]Cheng X,Zhang H,Lee HL,et al.Cyclooxygenase-2 inhibitor preserves medullary aquaporin-2 expression and prevents polyuria after ureteral obstruction.J Urol.2004,172(6Pt 1):2387-2390.
[36]Norregaard R,Jensen BL,Li C,et al.COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction.Am J Physiol Renal Physiol.2005,289(2):F322-F333.
[37]Breyer MD,Breyer RM.Prostaglandin receptors:their role in regulating renal function.Curr Opin Nephrol Hypertens.2000,9(1):23-29.
[38]Hebert RL.Cellular signalling of PGE2 and its selective receptor analogue sulprostone in rabbit cortical collecting duct.Prostaglandins Leukot Essent Fatty Acids.1994,51(3):147-55.
[39]EI-Haroun H,Bradbury D,Clayton A,et al.Interleukin-1[beta],transforming growth factor-[beta]1,and bradykinin attenuate cyclic AMP production by human pulmonary artery smooth muscle cells in response to prostacyclin analogues and prostaglandin E2 by cyclooxygenase-2 induction and downregulation of adenylyl cyclase isoforms 1,2,and 4.Circulation Research.2004,94(4):353-361.
[40]Hernandez J,AstudilloH,Escalante B.Angiotensin Ⅱ stimulates cyclooxygenase-2mRNA expression in renal tissue from ratswith kidneyfailure[J].Am J PhysiolRenalPhysio,2002,282(4):592 -598.
[41]刘红梅,黄体钢,王林,等.阿司匹林和氟伐他汀对血管紧张素Ⅱ诱导的血管平滑肌细胞环氧合酶2表达的抑制作用.中国动脉硬化杂志,2007,15(3):193-196.
[42]Eduard Stefan,Burkhard Wiesner,George S et al.Compartmentalization of cAMP-Dependent Signaling by Phosphodiesterase-4D Is Involved in the Regulation of Vasopressin-Mediated Water Reabsorption in RenalPrincipal Cells.J Am Soc Nephrol.2007,18(1):199-212.
[43]Nielsen S,Kwon TH,Mranster Christensen B,et al.Physiology and pathophysiology of renal aquaporins.J Am Soc Nephrol.1999,10(3):647-663..
[2]叶任高,阳晓.论慢性肾功能衰竭的进展机制和对策.中国医刊.2001,36(3):2-4.。
[3]Brenner BM,Meyer TW,Hostetter TH.Dietary protein and the progressive nature of kidney disease:The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging,renal ablation,and intrinsic renal disease.N Engl J Meal.1982,307(11):652-659.
[4]Schrier RW,Harris DCH,Chan L,et al.Tubular Hypermetabolism as a factor in the progression of chronic renal failure.Am J Kidney Dis.1988,12(3):243-249.
[5]王海燕.肾脏病学(第二版).北京:人民卫生出版社,1996:1385-426.
[6]张道友,孙亚南.慢性肾功能衰竭患者血脂质变化.中国动脉硬化杂志.1998,6(3):249-250.
[7]邹洪斌,王印全,崔明姬,等.老年肾脏疾病血清脂质水平的研究.中国老年学杂志.1999,19(3):158-159.
[8]上海市肾脏病心血管并发症调查协作组.上海地区透析患者血脂改变的调查.中华肾脏病杂志.2001,17(2):101-104.
[9]王云增,庄一义,汪俊军,等.慢性肾衰透析患者胆固醇酯转运蛋白及血脂变化.上海医学检验杂志.2000,15(1):39-41.
[10]安惠霞,刘素雁,任野平.血液透析对慢性肾功能衰竭患者血清脂质代谢的影响.哈尔滨医科大学学报.2001,35(6):438-439.
[11]樊均明,许国章.终末期肾功能不全患者高血压与血脂、脂蛋白和载脂蛋白的关系.临床内科杂志.1996,13(3):35-36.
[12]黄效维,麦慈光,梁波.慢性肾脏病患者血载脂蛋白AI的变化.安徽医学.2002,23(5):21-23.
[13]De-Gomez-Dumm NT,Giammona AM,Touceda LA,et al.Lipid abnormalities in chronic renal failure patients undergoing hemodiaiysis.Medicina-(B-Aires).2001,61(2):14-26.
[14]陈莉芬,李荣亨.肿瘤坏死因子在肾脏疾病中的研究进展.国外医学泌尿系统分册.2001,21(4):147-149.
[15]尹力.肾小管上皮细胞产生的细胞因子在肾间质纤维化中的作用.肾脏病与透析肾移植杂志.1994,3(4):309-311.
[16]李玲,邹万忠.肾小管和肿瘤坏死因子与间质纤维化的关系.肾脏病与透析肾移植杂志.1998,7(4):318-320
[17]吴华,许福照.内皮素与肾脏疾病.国外医学.泌尿系统分册.1994,14(6):250-253
[18]Pariclo N,R emuzzi G.Role of andothen in Glomerrular jnjury.Kidney Int,1993,43(39):576.
[19]Bruchu E,Lacasse S.Noreau C,et al.Endothelin ET(A) receptor blockade pevents the progression of renal falure and nypertension in uraemic rats.Nephrol Dial Transplant.1999,14(8):1881-1888.
[20]张晓蜂,王小春.慢性肾功能衰竭血浆内皮素含量变化.中华肾脏病杂志。1996,12(1):46.
[21]Yuqiang Ge,Dowahn Ahn,et al.Collecting duct-specific knockout of endothelin-1 alters vasopressin regulation of urine osmolality.Am J Physiol Renal Physiol.2005,288:F912.
[22].Mezzano SA,Ruiz-Ortega M,Egjdo J.Angiotensin II And Renal Fibrosis HyPertension .2001.38:635-638.
[23]Ruiz-ortega M,RuPerez M,Lorenzo O,et al.Angiotensin Ⅱ regulates the synthesis of Porinflammatory Cytokines and Chemokines in the kidney.Kidney Int.2002.62(supp182):S12-S22.
[24]林善锬,吴永贵.肾素-血管紧张素系统与肾脏疾病.中国实用内科杂志.1998,18(12):759-762.
[25]Suzuki Y,Ruiz-Ortega M,Lorenzo O.Inflammation and angiotensin Ⅱ.Int J Biochem Cell Biol.2003,35:881-900.
[26]Sttkru Oguzkan Topcu,Michael Pedersen,Rikke Nφrregaard,et al.Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction.Am J Physiol Renal Physiol.2007,292:F736-F748,
[27]Edwards RM,Stack EJ.Angiotensin Ⅱ inhibits glomerular adenylate cyclase via the angiotensin Ⅱ receptor subtype 1(AT1).J Pharmacol Exp Ther.1993,266(2):506-510,.
[28]Feria I,Pichardo I,Juarez P,et al.Therapeutic benefit ofspironolactone in experimental chronic cyclosporine Anephrotoxicity.Kidney Int.2003,63(1):43-52.
[29]Juknevicius I,Segal Y,Kren S,et al.Aldosterone causes TGF-8 expression(abstract).J Am Soc Nephrol.2000,11(3):622-627.
[30]Blasi ER,Rosenberg R,Rudolph AE,et al.Aldosterone/saltinduces renal inflammation and fibrosis in hypoertensive rats.Kidney Int.2003,63(5):1791-1800.
[31]李晓东,郭志军,高山林,等.醛固酮对肾小球系膜细胞合成分泌纤维连接蛋白的影响.山西医药杂志.2006,35(5):381-383.
[34]Cheng HF,Wang C J,Moeckel GW,et al.Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension.Kidney Int.2002,62(3)929-939.
[35]Wang JL,Cheng HF,Zhang MZ,et al.Selective increase of cyclooxygenase-2 expression in a model of renal ablation.Am J Physiol.1998,275(4 Pt 2):613-622.
[36]Wang JL,Cheng HF,Shappell S,et al.A selective cyclooxygenase-2 inhibition decrease proteinuria and retards progressive renal injury in rats.Kidney Int.2000,57(6):2334-2342.
[37]Miyajima A,Ito K,Asano T,et al.Does cyclooxygenase-2 inhibitor prevent renal tissue damage in unilateral ureteral obstruction.J Urol.2001,166(3):1124-1129.
[38]Norregaard R,Jensen BL,Li C,et al.COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction.Am J Physiol Renal Physiol.2005,289(2):F322-F333.
[39]王少华,张晶瑜,王彬.试论慢性肾功能衰竭正虚邪实之病机.上海中医药大学学报.2004,18(2):31-32.
[40]王永钧.肾功能衰竭的中医认识及对策.浙江中医杂志,1993,(1):49.
[41]屠立茵,何立群.慢性肾衰的中医辨证分型与治疗.中国医刊.2001,63(6):55-56.
[42]叶传蕙.中医药治疗慢性肾功能衰竭思路与方法.中国临床医生.2002,30(1):51-53
[43]傅文录.慢性肾衰中医多级辨治思路与方法探讨,新中医.1999,31(6):3-5.
[44]远方,叶任高.叶任高治疗慢性肾功能衰蝎经验集药.辽宁中医杂志.2001,28(6):336-337.
[45]江志勤.郑平东治疗慢性肾功能衰竭经验.安徽中医临床杂志.2001,13(6):458.
[46]焦安钦.慢性肾衰蝎病机特点与治疗对策.山东中医药大学学报.2001,25(3):290.
[47]张慧.皮持衡教授诊治慢性肾衰竭的临床经验,中国中西医结合肾病杂志.2004,5(2):68-71.
[48]孔庆欲.陆鸿滨教授辨证治疗慢性肾衰竭的经验.中国中西医结合肾病杂志2003,(7)375-376.
[49]吴金秀.慢性肾功能不全失代偿的可逆因素探讨.中国医学工程,2006,14(2):219-220.
[50]黄继义,张燕林,李弋南.慢性肾功能衰竭危险因素分析及防治措施探讨.福建医科人学学报,2004,38(1):94-95.
[51]常笑雪,黄鹂.水通道蛋白在肾脏的表达及意义.河南科技大学学报(医学版),2004,22(3):236-238
[52]Yang B,Song Y,Zhao D,et al.Phenotype analysis of aquaporin28 nullmice.AmJ Physiol Cell Physiol,2005,288(5):C116-C170
[53]Yakata K,Hiroaki Y,Ishibashi K,et al.Aquaporin-11 containing a divergent NPA motif has normal water channel activit-y.Biochim Biophys Acta,2007,1768(3):688-693.
[54]Moris hita Y,Matsuzaki T,Hara-chikuma M,et al.Disruption of aquaporin-11 produces polycystic kidneys following vacuolization of the proximal tubule.Mol Cell Biol,2005,25(17):7770-7779.
[55]Lee J,Yoo K S,Kang D Q,et al.Gentamicin decreases the abun 2 dance of aquaporin water channels in rat kidey.Jpn J Pharmacol,2001,85(4):391-398
[56]Apostol E,Ecelbarger C A,Terris J,et al.Reduced renal medullary water channel expression in puromycin aminonu 2 cleoside 2 induced nephrotic syndrome.J Am Soc Nephrol,1997,8(1):15-24.
[57]韩婷,胡同杰,耿姗姗,等.低钠低磷型蛋白质制剂改善慢性肾功能衰竭患者营养状况的效果.中国营养杂志,2005,13(4):238-241.
[58]崔明,欧阳淑娟.慢性肾功能衰竭患者重组人红细胞生成素疗效观察.医学临床研究,2005,8,1172-1173.
[59]张萍,梁劲松.大剂量促红细胞生成素治疗肾性贫血的疗效观察.中国药房.2005,16(13):1009-1010.
[60]Mallwhe HH,Mawad H.Management of hyperpba Omtaenia of chreic kidney diseus lessons from the past and fut ure directione.Nephrol Dial Transphant.2002,17(7):1170-1175。
[61]Hervm J G,Pmdm D,Cemzo S.Treannerrt of hyperphos phatenua wit h ovelwrer hydmddmide in hemodidysis pulienla:Acomparism wit h calcium acetate.Kidney Int Suppl.2003,(85):69-721
[62]陈莉,刘英.中西医结合治疗慢性肾功能不全疗效观察.辽宁中医杂志.2006,33(7):852-853.
[63]付平,周莉等.氯沙坦治疗慢性肾功能不全合并高尿酸血症的疗效观察.中国全科医学.2004,7(24):1854-1855.
[64]Cross J.Endothelial dysfunction in uraemia.Blood Punif.2002,20(5):456-459.
[65]伍锦泉,潘志铣,陈玉平,等.探讨氧化应激和炎症反应在慢性肾功能衰竭(CRF)患者内皮功能失调和动脉粥样硬化中的作用.中国基层医药.2006,13(4):641-642.
[66]Sorensenke,celermajer DS,Georgakopoulos,et al,Impairment of endot heliumdependent dilation is an early event in children with familial hypercholesterolemia and is related to lipoprotein(a)level.Chin Invest.1994,93(1):50-55.
[67]丁品,李健.血管内皮功能障碍与冠脉疾病关系及防治进展.中国全科医学.2005,8(23):1977-1978.
[68]朱冬菊,张玲.慢性肾衰竭的抗氧化治疗.中国血液透析.2006,5(2):91-941
[69]康宁,高慧,李岩,位东卫.右归丸在血液透析患者中的临床应用.医药世界.2006,(9):123.
[70]王济生.慢性肾衰竭中医治疗探讨山东中医杂志.2004,23(12):709-711.
[71]张金华,万亮瑜.中医治疗慢性肾功能衰竭体会.中华现代中医学杂志.2006,2(8):706-707.
[72]栾洪文,王天祥,马彩霞.中医治疗慢性肾功能衰竭的几种方法.中国临床医药研究杂志.2003,92:9140.
[73]肖相如.温阳法在慢性肾衰中的运用。北京中医药大学学报.2005,28(5):86-87.
[74]杨应兄,孙红旭,薛国忠.戴恩来老师治疗慢性肾功能衰竭经验.甘肃中医.2007,20(3):8-9
[75]傅晓骏,张慧嫦,刘瑾.肾毒宁治疗慢性肾衰竭62例临床研究.中国中西医结合肾病杂志.2004,5(10):607-608.
[76]廖竹芬.复方丹参注射液合温阳通利方治疗慢性肾衰30例.中国中医药科技.2006,13(4):276.
[77]廖竹芬.复方丹参注射液合温阳通利方治疗慢性肾衰30例疗效观察.新中医.2005,37(4):54-55.
[78]王身菊,朱成英.益气养阴和络泄浊法治疗慢性肾功能衰竭46例疗效观察.新中医.2003,35(4):18-20.
[79]何灵芝,李学铭.补阳还五汤治疗肾病举隅.广西中医药.2005,28(6):34.
[80]易晓颖,陈彤,舒惠荃.中西医结合治疗慢性肾衰的临床观察.成都中医药大学学报,2000,23(4):49-50.
[81]沈维增,谢峥伟,吕红梅.温阳利水、化瘀泄浊法延缓慢性肾功能衰竭进展临床研究.中国中医药信息杂志.2007,14(4):17-18.
[82]王皓.肾宁康对肾衰大鼠肾组织丙二醛等指标的影响.辽宁中医杂志2005,32(4):373-374.
[83]吴佳武.温阳清浊汤治疗慢性肾功能衰竭临床观察.湖北中医学院学报.2007,9(4):47.
[84]段淑兰,陈小仙,蒋鹏.中药为主治疗慢性肾功能不全40例临床观察.河南中医.2004,5(24):36-37
[85]王暴魁,张军,刘震等.温脾清化汤治疗慢性肾功能不全的临床观察.中国医药学报.2003,18(6):341-343.
[86]来永兰,孙文芹,安良毅等.祛湿温阳汤灌肠治疗慢性肾功能不全临床察.中国中西医结合急救杂志.2003,10(4):247-248.
[87]周竹,李俊,周梅,等尿毒清颗粒治疗早中期慢性肾功能衰竭的临床观察.中华临床医药杂志.2001,2(11):21-23.
[88]史伟尿毒清冲剂治疗慢性肾衰竭的临床观察.中国中西医结合肾病杂志.2001,9(12):734-735.
[89]靖新文.肾毒清冲剂治疗慢性肾衰竭110例.山东中医药大学学报.2000,24(6):19.
[90]王怡,何立群,郑平东.抗纤灵冲剂改善慢性肾衰竭实验兔血液动力学及肾小球硬化的研究.上海中医药大学学报.2000,14(2):47-49.
[91]王济生,陈丽霞,元琦.肾康灵治疗慢性肾衰竭临床观察.山东中医药大学学报.2000,24(1):31-33.
[92]何立群,郑平东,朱燕俐,等.肾衰冲剂对慢性肾功能衰竭动物肾组织的影响.上海中医药大学学报.2000,14(2):50-51.
[93]王小琴,邵朝弟,谭大琦,等.肾安颗粒治疗慢性肾衰竭的临床观察.中国中西医结合肾病杂志.2003,4(7):393-395.
[94]阮诗伟,郑敏麟,陈建,等.益肾降浊冲剂治疗慢性肾衰竭的实验研究.中国中西医结合肾病杂志.2003,4(9):506-509.
[95]王志红.大黄治疗慢性肾功能衰竭172例疗效分析.中国综合临床.2005,21(4):332-333.
[96]周钦,曹文富,李荣亨.大剂量黄芪注射液对慢性肾功能不全患者血浆、尿液内皮素的 影响.中国中药杂志.2001,26(3):200-201.
[97]张颖,张士英,王微,等.黄芪注射液对慢性肾衰竭免疫功能的影响.长春中医学院学报.2000,16(2):28.
[98]刘杰,杜学海,傅芳婷,等.人参皂甙清除反应性氧代谢产物预防大鼠膜性肾病.肾脏病与透析肾移植杂志.1995,4(1):29-31
[99]杨俊伟,黎磊石.冬虫夏草与肾冷缺血-再灌注损伤的研究.肾脏病与透析肾移植杂志,1995,4(1):21..
[100]程庆珠,于力方,师锁柱,等.冬虫夏草对5/6肾切除大鼠肾脏病理改变的影响.中华肾脏病杂志.1994,10(1):30
[101]唐树德,王崇行,钱珠,等.首乌治疗早期肾脏损害血瘀型高血压患者28例.中国中西医结合杂志.1994,14(5):302-305.
[102]张国强,叶任高,孔庆瑜,等.丹参对狼疮性肾炎成纤维细胞增殖凋亡、及c-myc蛋白表达的影响[J].中国中西医结合杂志.1997,17(8):473-475.
[103]刘云苗.川芎嗪对慢性肾衰患者肾血流量和肌酐清除的影响.中国中西医结合杂志.1993,13(2):107
[104]杨学峰,杨海棠,张香勤.口服中药合灌肠泄浊加西医治疗慢性肾功能衰竭71例临床观察.四川中医.2003,21(2):23-24.
[105]韦明欣.大黄为主灌肠治疗慢性肾功能衰竭的疗效观察.广西医学.1995,17(5):4281.
[106]韩旭,陈美兰.中药保留灌肠治疗慢性肾功能衰竭58例临床观察.山西中医.1995,11(3):13.
[107]朱红云.治疗慢性肾功能衰竭42例临床观察.上海中医药杂志.1997,(5):23.
[108]李林芳,段淑云.改进中药保留灌肠法治疗慢性肾功能不全51例疗效观察.实用中西医结合临床.2006,6(6):57-58.
[109]张宇梅,王亚平,霍延红等.结肠透析治疗老年慢性肾功能衰竭的临床研究.实用诊断与治疗杂志.2007,21(12):888-889.
[110]王亚平,王志忠,李浩等.应用JS-308结肠透析机配合中药治疗慢性肾功能衰竭的临床研究.华北国防医药.2006,18(5):318-319.
[1]杜卉莲,傅晓晴.慢性肾衰动物的模型制备及临床应用.中医研究.2005,18(12):53-57.
[2]熊宁宁,董筱玉,何原惠,等.维护肾元中药治疗大白鼠慢性肾衰的实验研究.中华肾脏病杂志.1989,5(3):187-189.
[3]王耀光.肾皮质电灼所致慢性肾功能衰竭动物模型血癖初探.河南中医.1997,17(1)22-24.
[4]傅晓晴,林若勤,武一曼,等.腺嘌呤制作肾阳虚型慢性肾功能衰竭大鼠模型的生化研究,福建中医学院学报.2003,13(1):22-24.
[5]Wenning J J,Rennke G.Glomerular permeability and polyanion in Adriamycin nephrosis in the rat.Kidney Int.1983;24(2):152- 159.
[6]姜新酞,胡明昌.柔红霉素肾病:活性氧诱发脂质过氧化反应引起的肾组织损伤,中华肾脏病杂志.1991,7(2):74-76.
[7]王海燕.肾脏病学.北京:人民卫生出版社,1996,967-982.
[8]Barty M.Brenner.Brenner&Rector's The Kindey.北京:科学出版社,2001,1563-1585,1820-1868,1236.
[9]周静,爱民,王朝阳.腺嘌呤制作慢性肾功能衰竭大鼠疾病模型.内蒙古医学院学报.2004,26(4):248-252.
[10]赵海峰,张召峰.腺嘌呤制备大鼠慢性肾功能损伤的模型.癌变·畸变·突变.2008,20(5):376-379.
[11]肖相如.温阳法在慢性肾衰中的运用.北京中医药大学学报.2005,5(28):86-87.
[12]李佑生.温法治疗慢性肾衰研究进展.湖南中医学院学报.1992,12(2):59-62.]
[13]康宁,高慧,李岩,等.右归丸在血液透析患者中的临床应用.医药世界.2006,(9):123.
[14]王济生.慢性肾衰竭中医治疗探讨山东中医杂志.2004,23(12):709-711.
[15]张金华,万亮瑜.中医治疗慢性肾功能衰竭体会.中华现代中医学杂志.2006,2(8):706-707.
[16]申志强.慢性肾功能衰竭的水电解质紊乱其处理.中原医刊.1988,(2):44-47.
[17]阎祝三.慢性肾功能衰竭的非透析治疗.中国实用内科杂志.1998,18(6):332。
[18]Druere TB,Eckardtku KU,Frei U,et al.Does early anemiacorrection prevert complications of chronic renal failure.Clin Nephrol.1999,51(1):1 -11.
[19]黄继义,张燕林等.慢性肾功能衰竭危险因素分析及防治措施探讨.福建医科大学学报.2004,38(1):94-95..
[20]吴金秀.慢性肾功能不全失代偿的可逆因素探讨.中国医学工程.2006,14(2):219-220.
[21]刘鹏,陶汉华.肾气丸与右归丸补肾机理异同辨.河南中医.2008,28(4):67.
[22]焦淑芳,喻红.温阳通腑降浊法治疗慢性肾衰竭阳虚浊毒证疗效观察.湖南中医学院学报.2001.21(2):51-52.
[23]唐青.黄芪、附子等对慢性肾功能衰竭病人UA,HDLC的影响.中华名医论坛,2005,(2):58-59.
[24]韩家强,李仁善.温脾汤治疗慢性肾衰脾肾阳虚证对肾血流动力学的影响.黑龙江中医药.2001,(1):1.
[25]黄桂香.当归生物学效应研究.时珍国医国药.2001.12(3):262-263.
[26]穆守俊.中医药治疗慢性肾功能衰竭近况.河北中医.2001,23(2):155.
[27]黄黎明,梁恒,邢建宇.山茱萸提取物对慢性肾炎小鼠的药理作用及蛋白质组学效应的实验研究.中国药理学通报.2004,20(10):1144-50.
[28]熊玉兰,王金华,屠国瑞,等.熟地黄麦角甾苷对小鼠肾毒血清肾炎治疗作用的研究.世界科学技术.中医药现代化基础研究.2006,8(5):46-48
[1]杜卉莲,傅晓晴.慢性肾衰动物的模型制备及临床应用.中医研究.2005,18(12):53-57.
[2]Preston GM,Carroll TP,Guggino WB,et al.Appearance of water channels in xenops oocytes expressing red cell CHIP28 protein.Science.1992,256(5055):385-387.
[3]Kazuyoshi Muarta,Kaour Mitsuoka,Teurhisa Hiari,et ai.Structural determinants of water permeation through aquaporin-1.Nature.2000,407(6804):599-605.
[4]Haixin Sui,Bong Gyoon Han,John K Lee,et al.Structural basis of water specific transport through the AQP1 water channel. Nature.2001,414(6866):872-878.
[5]]Nielsen S, Frokiaer J, Marples D, et al. Aquaporins in the kidney: from molecules to medicine. Physiol. Rev 2002, 82(1):205-244.
[6]Eun Jin Sohn, Dae Gill Kang, Ho Sub Lee. Protective Effects of Glycyrrhizin on Gentamicin-Induced Acute Renal Failure in Rats.Pharmacology Toxicology. 2003, 93(3):116-122.
[7]Gong H, Wang WD, Tae Hwan K, et. al. Reduced renal expression of AQP2, P-AQP2 and AQP3 in haemorrhagic shock induced acute renal failure.Nephrol Dial Transplant. 2003, 18(12):2551-2559.
[8]Sabolic J, KatsuraY, Verbabatz JM, etal .The AQP2 water channel:effect of vasopressin treatment, microtubule disruption, and distribution in neonatal rats.J Member Biol. 1995,143(3):165-175.
[9]Knepper MA, Verbulif TG, Nielsen S. Role of aquaporins in water balance disorders.Curr Oprin Nephrol and Hyer.l997,6(4):367-371.
[10]Marples D,Frokiaer J,Dorup J,Knepper MA,et al.Hypokalemia induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Clin Invest. 1996,97(8): 1960-1968.
[11]Earm JH, Christensen BM, Frokiaer J, et al.Decreased aquaporin-2 expression and apical plasma membrane delivery in kidney collecting ducts of polyuric hypercalcemic rats. J Am Soc Nephrol.1998,9(12):2181-2193.
[12] Wang W, Li C, Kwon TH, et al. AQP3, p-AQP2,and AQP2 expression is reduced in polyuric rats with hypercalcemia: prevention by CAMP-PDE inhibitors. Am J Physiol Renal Physiol.2002, 283(6): F1313-F1325.
[13]Marples D, Christensen S, Christensen EI, et al. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest. 1995, 95(4):1838-1845.
[14]Kwon TH, Frokiaer J, Fernandez-Llama P, et al. Reduced abundance of aquaporins in rats with bilateral ischemia-induced acute renal failure: prevention by alpha-MSH. Am J Physiol.1999,277(3 Pt 2):F413-F427.
[15]Apostol E,Ecelbarger CA,Terris J,et al.Reduced renal medullary water channel expression in puromycin aminonu-cleoside-induced nephrotic syndrome[J].J Am Soc Nephrol.1997,8(1):15-24.
[16]Tae-Hwan Kwon,Jφrgen Frφkiaer,Mark A.Knepper,et al.Reduced AQP1,-2,and -3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass Am J Physiol Renal Physiol,1998,275(5):F724-F741.
[17]Frokiaer J,Li C,Shi Y,et al.Renal aquaporins and sodium transporters with special focus on urinary tract obstruction.APMIS Suppl.2003,(109):71-79.
[18]Li C,Wang W,Kwon TH,et al.Downregulation of AQP 1,2,and 3 after ureteral obstruction is associated with a long-term urine-concentrating defect.Am J Physiol Renal Physiol.2001,281(1):F163-F171.
[19]Li C,Wang W,Knepper MA,et al.Downregulation of renal aquaporins in response to unilateral ureteral obstruction.Am J Physiol Renal Physiol.2003,284(5):F1066-F1079.
[20]Xu D,Yin X,Hui H,et al.Urinary excretion of aquaporin-2 channel protein in chronic heart failure rats.Chin Med J(Engl).2001,114(9):899-901.
[21]Asahina Y,Izumi N,Enomoto N,et al.Increased gene expression of water channel in cirrhotic rat kidneys.Hepatology.1995,21(1):169-173.
[22]Ohara M,Martin PY,Xu DL,et al.Upregulation of aquaporin 2 water channel expression in pregnant rats.J Clin Invest.1998,101(5):1076-1083.
[23]Deen PM,Verdijk MA,Knoers NV,et al.Requirement of human renal water channel aquaporin-2 for vasopressin-dependent conccntration of urine.Science.1994,264(5155):92-95.
[24]李屹,何立群.肾阳虚大鼠模型的水通道蛋白1改变.中西医结合学报.2008;6(5):498-501
[25]冼绍祥,欧明.肾阳虚型心力衰竭肾脏髓质水通蛋白的表达的实验研究.成都中医药大学学报.2007,30(2):39-41
[26]尧敏.济生肾气丸加减治疗中老年水肿100例.江苏中医药.2002,23(3):18.
[27]叶青补肾缩泉汤治疗老年男性夜尿增多24例.河北中医.2006,28(3):184.
[28]李凤辉金匮肾气丸合五苓散治疗尿崩症.山东中医杂志.2006,25(2):137-138.
[29]马步升,常景梅.中药治疗老年夜间多尿64例.广西中医药.1997,20(2):22.
[30]苟海峰.右归丸加减调治老年男性夜尿频数30例.辽宁中医学院学报.2004,6(4):103.
[31]陈旺全.妇女夜尿之治疗.台湾中医临床医学杂志.2007,13(2):114-116.
[32]陈素芝.同房遗尿治验.陕西中医.1994,15(6):272.
[1]杜卉莲,傅晓晴.慢性肾衰动物的模型制备及临床应用.中医研究.2005,18(12):53-57.
[2]]Nielsen S,Frokiaer J,Marples D,et al.Aquaporins in the kidney:from molecules to medicine.Physiol.Rev 2002,82(1):205-244.
[3]Knepper MA,Wade JB,Terris J,et al..Renal aquaporins.Kidney Int.1996,49(6):1712-1717.
[4]Brown D.The ins and outs of aquaporin-2 trafficking.Am J Physiol Renal Physiol.2003,284(5):F893-F901.
[5]Katsura T,Gustafson CE,Ausiello DA,et al.Protein kinase A phosphorylation is involved in regulated exoeytosis of aquaporin-2 in transfected LLC-PKI cells.Am J Physiol.1997,272(6 Pt 2):F817-F822.
[6]Brown D,Katsura T,Gustafson CE.Cellular mechanisms of aquaporin trafficking.Am J Physiol Renal Physiol.1998,27(3):328-331.
[7]Hasler U,Mordasini D,Bens M,et al.Long term regulation of aquaporin2 expression in vasopressin responsive renal collecting duct principal cells.J Biol Chem.2002,277(12):10379-10386.
[8]Knepper MA. Long-term regulation of urinary concentrating capacity. Am J Physiol.1998, 275(3 Pt 2):F332-F333.
[9]De Wardener HE, Herxheimer A. The effect of a high water intake on the kidney's ability to concentrate the urine in man. J Am Soc Nephrol.2000, 11(5):980-987.
[10]Lankford SP, Chou CL, Terada Y, et al. Regulation of collecting duct water permeability independent of cAMP-mediated AVP response.Am J Physioll.1991,261(3 Pt 2):F554- F566.
[11]DiGiovanni SR, Nielsen S, Christensen EI, et al. Regulation of collecting duct water channel expression by vasopressin in Brattleboro rat. Proc Natl Acad Sci U S A. 1994, 91(19):8984-8988.
[12]Nielsen S,Chou CL, Marples D, et al.Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci U S A. 1995, 92(4):1013-1017.
[13] Terns J, Ecelbarger CA, Nielsen S, et al. Long-term regulation of four renal aquaporins in rats. Am J Physiol.1996, 271(2 Pt 2):F414-F422.
[14]Ma T, Hasegawa H, Skach WR, et al. Expression, functional analysis, and in situ hybridization of a cloned rat kidney collecting duct water channel. Am J Physiol. 1994, 266(1 Pt 1):C189-C197.
[15]Yamamoto T, Sasaki S, Fushimi K, et al. Vasopressin increases AQP-CD water channel in apical membrane of collecting duct cells in Brattleboro rats. Am J Physiol. 1995, 268(6 Pt 1):C1546-C1551
[16]Jawadi, M. H., L. S. Ho, D. Dipette, et al. Ross.Regulation of plasma arginine vasopressin in patients with chronic renal failure maintained on hemodialysis. Am. J. Nephrol.1986,6(3):175-181.
[17]Bouby, N., S. Bachmann, D. Bichet, L. Bankir. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am. J. Physiol. 1990, 258 (4 Pt 2):F973-F979.
[18]Kwon, Tae-Hwan, J0rgen Fr(?)kiaer, et al. Reduced AQP1, -2, and -3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass.Am.J Physiol.1998,275(5 Pt 2):F724-F741.
[19]Michelle Boone,Peter M.T.Deen Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption.Pflugers Arch..2008,456(6):1005-1024.
[20]Kaschina E,Unger T.Angiotensin AT1/AT2 receptors:regulation,signalling and function[J].Blood Press.2003,12(2):70-88.
[21]Johnson RJ,Alpers CE,Yoshimura A,et al.Renal injury from angiotensin Ⅱ mediated hypertension.Hypertension.1992,19(5):464-474
[22]Satoh M,Kashihara N,Yamasaki Y,et al.Renal interstitial fibrosis is reduced in angiotensinⅡ type la receptor-deficient mice.J Am Soc Nephrol.2001,12(2):317-325
[23]Fern RJ,Yesko CM,Thornhill BA,et al.Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice.J Clin Invest.1999,103(1):3 9-46
[24]Mezzano SA,Ruiz-Omega M,Egido J.Angiotensin Ⅱ and Renal Fibrosis.Hypertension.2001,38:635-638.
[25]Jensen AM,Li C,Praetorius HA,et al.Angiotensin Ⅱ mediates downregulation of aquaporin water channels and key renal sodium transporters in response to urinary tract obstruction.Am J Physiol Renal Physiol.2006,291(5):F 1021-32.
[26]Kim E.J,Jung Y.W.,Kwon T.H.Angiotensin Ⅱ AT1 receptor blockade changes expression of renal sodium transporters in rats with chronic renal failure.J Korean Med Sci.2005,20(2):248-255.
[27]Sukru Oguzkan Topcu,Michael Pedersen,Rikke Nφrregaard,et al.Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction Am J Physiol Renal Physiol.2007,292(2):F736-F748.
[28]Edwards RM,Stack EJ.Angiotensin Ⅱ inhibits glomerular adenylate cyclase via the angiotensin Ⅱ receptor subtype 1(AT1).J Pharmacol Exp Ther.1993,266(2):506-510.
[29]刘敏,张桦,陈宏,等.血管紧张素Ⅱ对离体人胰岛细胞内游离Ca~(2+)及cAMP的影响.广东医学.2007,28(9):1395-1397.
[30]Ozturk H,Ozdemir E,Otcu S,et al.Renal effects on a solitary kidney of specific inhibition of cyclooxygenase-2 after 24 h of complete ureteric obstruction in rats.Urol Res.2002.30(4):223-226.
[31]Wang JL,Cheng HF,Zhang MZ,et al.Selective increase of cyclooxygenase-2 expression in a model of renal ablation.Am J Physiol.1998,275(4 Pt 2):F613-622.
[32]杨健,唐琳,刘章锁,等.罗非昔布对单侧输尿管梗阻大鼠肾间质纤维化的改善作用.郑州大学学报(医学版).2006,41(3):527-529.
[33]左怡沁,马骥,顾勇,等.环氧合酶在单输尿管梗阻大肾脏的表达.上海医学.2002,25(5):285。
[34]Ricardo SD,Ding G,Eufemio M,et al.Antioxidant expression in experimental hydronephrosis:role of mechanical stretch and growth factors.Am J Physiol Renal Physiol.1997,272(6 Pt 2):F789-F798.
[35]Cheng X,Zhang H,Lee HL,et al.Cyclooxygenase-2 inhibitor preserves medullary aquaporin-2 expression and prevents polyuria after ureteral obstruction.J Urol.2004,172(6Pt 1):2387-2390.
[36]Norregaard R,Jensen BL,Li C,et al.COX-2 inhibition prevents downregulation of key renal water and sodium transport proteins in response to bilateral ureteral obstruction.Am J Physiol Renal Physiol.2005,289(2):F322-F333.
[37]Breyer MD,Breyer RM.Prostaglandin receptors:their role in regulating renal function.Curr Opin Nephrol Hypertens.2000,9(1):23-29.
[38]Hebert RL.Cellular signalling of PGE2 and its selective receptor analogue sulprostone in rabbit cortical collecting duct.Prostaglandins Leukot Essent Fatty Acids.1994,51(3):147-55.
[39]EI-Haroun H,Bradbury D,Clayton A,et al.Interleukin-1[beta],transforming growth factor-[beta]1,and bradykinin attenuate cyclic AMP production by human pulmonary artery smooth muscle cells in response to prostacyclin analogues and prostaglandin E2 by cyclooxygenase-2 induction and downregulation of adenylyl cyclase isoforms 1,2,and 4.Circulation Research.2004,94(4):353-361.
[40]Hernandez J,AstudilloH,Escalante B.Angiotensin Ⅱ stimulates cyclooxygenase-2mRNA expression in renal tissue from ratswith kidneyfailure[J].Am J PhysiolRenalPhysio,2002,282(4):592 -598.
[41]刘红梅,黄体钢,王林,等.阿司匹林和氟伐他汀对血管紧张素Ⅱ诱导的血管平滑肌细胞环氧合酶2表达的抑制作用.中国动脉硬化杂志,2007,15(3):193-196.
[42]Eduard Stefan,Burkhard Wiesner,George S et al.Compartmentalization of cAMP-Dependent Signaling by Phosphodiesterase-4D Is Involved in the Regulation of Vasopressin-Mediated Water Reabsorption in RenalPrincipal Cells.J Am Soc Nephrol.2007,18(1):199-212.
[43]Nielsen S,Kwon TH,Mranster Christensen B,et al.Physiology and pathophysiology of renal aquaporins.J Am Soc Nephrol.1999,10(3):647-663..